Note 15 - Segments (Tables)

3 Months Ended

Mar. 31, 2018

T hree Months Ended March 31, 2018	Diagnostics			Therapeutics			Corporate			Total
Tc99m tilmanocept royalty revenue	$	795		$	—		$	—		$	795
Grant and other revenue		232,436			43,214			—			275,650
Total revenue		233,231			43,214			—			276,445
Cost of goods sold		318			—			—			318
Research and development expenses		785,011			213,945			—			998,956
Selling, general and administrative expenses, excluding depreciation and amortization (1)		—			8,607			1,729,778			1,738,385
Depreciation and amortization (2)		—			—			37,987			37,987
Loss from operations (3)		(552,098	)		(179,338	)		(1,767,765	)		(2,499,201	)
Other expense (4)		—			—			(4,238,761	)		(4,238,761	)
Net loss		(552,098	)		(179,338	)		(6,006,526	)		(6,737,962	)
Total assets, net of depreciation and amortization:
United States	$	13,077,979		$	27,228		$	5,189,637		$	18,294,844
International		26,055			—			1,328			27,383
Capital expenditures		—			—			—			—

T hree Months Ended March 31, 2017	Diagnostics			Therapeutics			Corporate			Total
Grant and other revenue	$	571,362		$	8,668		$	—		$	580,030
Research and development expenses		413,202			292,072			—			705,274
Selling, general and administrative expenses, excluding depreciation and amortization ( 1 )		—			2,521			2,943,123			2,945,644
Depreciation and amortization ( 2 )		—			—			76,790			76,790
Income (loss) from operations ( 3 )		158,160			(285,925	)		(3,019,913	)		(3,147,678	)
Other expense		—			—			(1,171,109	)		(1,171,109	)
Income tax (expense) benefit		(53,254	)		96,273			1,411,153			1,454,172
Net income (loss) from continuing operations		104,906			(189,652	)		(2,779,869	)		(2,864,615	)
Loss from discontinued operations, net of tax		(255,861	)		—			—			(255,861	)
Gain on sale of discontinued operations, net of tax		88,701,501			—			—			88,701,501
Net income (loss)		88,550,546			(189,652	)		(2,779,869	)		85,581,025
Total assets, net of depreciation and amortization:
United States	$	9,692,007		$	897		$	23,116,511		$	32,809,415
International		115,279			—			893			116,172
Capital expenditures		—			—			—			—